Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indoximod + Gemcitabine + Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT02077881Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Aug 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of indoximod in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Lumos Pharma, Inc. Primary endpoints: Regimen Limiting Toxicity at 10 months and Overall Survival at 22 months. Started Aug 2014; status: completed.
02
Drugs
indoximod
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02077881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077881.